Advances in the LI-RADS Treatment Response Algorithm: Imaging Principles, Diagnostic Challenges, and Clinical Integration Following the LI-RADS 2024 Update.
6 affiliations
- 1Programme of Radiology, Faculty of Allied and Healthcare Sciences, Assam Down Town University, Guwahati, Assam, India.
- 2Department of Urology and Renal Transplant, Gauhati Medical College and Hospital, Guwahati, Assam, India.
- 3Division of Pre-college and Undergraduate Studies, Brown University, Providence, RI, USA.
- 4School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin, 300131, People's Republic of China.
- 5School of Engineering, Saveetha University, Chennai, India.
- 6Department of Pharmacy, The University of the Basque Country, Vitoria-Gasteiz, Spain.
Abstract
Hepatocellular carcinoma (HCC) management has evolved rapidly with the expanding use of locoregional therapies, systemic agents, and modern immunotherapy combinations. These advances have introduced complex and variable post-treatment imaging appearances, underscoring the need for refined, standardized criteria to accurately differentiate viable tumors from treatment-related changes. The updated LI-RADS Treatment Response Algorithm (v2024-2025) incorporates new guidance on arterial enhancement, washout, ancillary features, and modality-specific considerations to improve consistency and diagnostic clarity. This review synthesizes these updates and their implications for clinical practice. A comprehensive narrative review was conducted using updated LI-RADS guidelines and recent literature evaluating CT, MRI, CEUS, dual-energy CT, and photon-counting CT for post-treatment HCC assessment. Therapy-specific imaging appearances, algorithmic refinements, pitfalls, radiologic-pathologic correlations, and applications of artificial intelligence were analyzed. The updated LI-RADS TRA has shown potential lesion-level assessment by clarifying criteria for viable, non-viable, and equivocal responses. Multiparametric MRI and spectral CT improve the detection of subtle viable tissue, while advanced imaging helps address confounding factors such as granulation tissue, perfusional changes, and immune-related pseudo-progression. The algorithm demonstrates high accuracy after ablation and TACE, with ongoing refinements needed for radiotherapy and immunotherapy. Radiomics and machine learning models show strong potential for automated viability assessment and early prediction of recurrence. The LI-RADS TRA (v2024-2025) strengthens standardization of post-treatment HCC imaging and supports more accurate, reproducible interpretation across modalities. As treatment options expand, integrating quantitative imaging biomarkers and AI-driven tools will be essential for personalized treatment planning and improved clinical outcomes.
Related
- A Case of Refractory Anti-GABAAR Encephalitis: Diagnostic Insights and Treatment Challenges
- Sacral spinal dural arteriovenous fistula: diagnostic pitfalls and treatment challenges. Illustrative case
- Mycobacterium fortuitum: Diagnostic and treatment challenges of skin disease in an immunocompetent host.
- External Validation of a Treatment Decision Algorithm for Tuberculosis in Children Living with HIV: A Diagnostic Cohort Study
- Simulation-guided outlet valve repair: early integration of computationally-derived principles of free-edge length in bicuspidization repair
BibTeX
@article{sarma2026advances,
title = {{Advances in the LI-RADS Treatment Response Algorithm: Imaging Principles, Diagnostic Challenges, and Clinical Integration Following the LI-RADS 2024 Update.}},
author = {Arnabjyoti Deva Sarma and Debanga Sarma and Thomas J Webster},
journal = {Cancer management and research},
year = {2026},
month = oct,
doi = {10.2147/cmar.s614483},
url = {https://europepmc.org/article/MED/42927357},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Advances in the LI-RADS Treatment Response Algorithm: Imaging Principles, Diagnostic Challenges, and Clinical Integration Following the LI-RADS 2024 Update.
AU - Arnabjyoti Deva Sarma
AU - Debanga Sarma
AU - Thomas J Webster
PY - 2026
DA - 2026/10/20
JO - Cancer management and research
DO - 10.2147/cmar.s614483
UR - https://europepmc.org/article/MED/42927357
AB - Hepatocellular carcinoma (HCC) management has evolved rapidly with the expanding use of locoregional therapies, systemic agents, and modern immunotherapy combinations. These advances have introduced complex and variable post-treatment imaging appearances, underscoring the need for refined, standardized criteria to accurately differentiate viable tumors from treatment-related changes. The updated LI-RADS Treatment Response Algorithm (v2024-2025) incorporates new guidance on arterial enhancement, washout, ancillary features, and modality-specific considerations to improve consistency and diagnostic clarity. This review synthesizes these updates and their implications for clinical practice. A comprehensive narrative review was conducted using updated LI-RADS guidelines and recent literature evaluating CT, MRI, CEUS, dual-energy CT, and photon-counting CT for post-treatment HCC assessment. Therapy-specific imaging appearances, algorithmic refinements, pitfalls, radiologic-pathologic correlations, and applications of artificial intelligence were analyzed. The updated LI-RADS TRA has shown potential lesion-level assessment by clarifying criteria for viable, non-viable, and equivocal responses. Multiparametric MRI and spectral CT improve the detection of subtle viable tissue, while advanced imaging helps address confounding factors such as granulation tissue, perfusional changes, and immune-related pseudo-progression. The algorithm demonstrates high accuracy after ablation and TACE, with ongoing refinements needed for radiotherapy and immunotherapy. Radiomics and machine learning models show strong potential for automated viability assessment and early prediction of recurrence. The LI-RADS TRA (v2024-2025) strengthens standardization of post-treatment HCC imaging and supports more accurate, reproducible interpretation across modalities. As treatment options expand, integrating quantitative imaging biomarkers and AI-driven tools will be essential for personalized treatment planning and improved clinical outcomes.
SN - 1179-1322
ER -